English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The emerging Corona virus strain (severe acute respiratory syndrome corona virus-2 (SARS-CoV-2)) harbors intricate pathogenicity in the development of corona virus infection (COVID-19)-induced pneumonia and subsequently ameliorates lung infection Genome sequence and phylogenetic interventions reveal proximal resemblance of corona virus strain COVID-19 with severe acute res-piratory syndrome (SARS), transmittable to bats, suggesting similar primary hosts in the spread of infection However, potential rapid human-to-human transmission has caused therapeutic chal-lenges in treating a wide range of humans suffering from corona virus all over the world However, up to now, no direct vaccines or antiviral drugs are available to treat COVID-19 Previously designed antiviral drugs and convalescent plasma are undergoing investigations as treatment for COVID-19 infected patients Therapeutic challenges with regards to COVID-19 have prompted scientists to develop fruitful remedies to combat the pathogen In this review, we address the role of current ongoing therapeutic strategies, immunogenomics, and complex mechanisms of adaptive immune system (B and T cells) to respond to viruses Furthermore, we illustrate the current challenges in the treatment of COVID-19, managerial strategies, and ongoing and future perspectives

biomedical research and therapy

Novel immunogenomic insights of corona virus disease (COVID-19): Available potential immunotherapeutics, current challenges, immune cell recognition and ongoing managerial strategies